MTNB Stock Catalyst: Matinas BioPharma Granted U.S. Patent for Encochleated Antifungal Compounds

Aug 19, 2026 · 3:57pm ET

The patent is for central nervous system delivery and treatment of Cryptococcus infections.

Max move

+34.2%

High of day $0.27

Sparker timei

3:57pm ET

MTNB · Aug 19, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled "ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS".

The patent covers the company's innovative approach to delivering antifungal compounds to the central nervous system for the treatment of Cryptococcus infections.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time MTNB sparks.

Download Sniper App →

Catch the next MTNB-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →